156 related articles for article (PubMed ID: 28611315)
1. The tuberous sclerosis complex gets fatter.
Gokare P; El-Deiry WS
Oncotarget; 2017 Jun; 8(26):41780-41781. PubMed ID: 28611315
[No Abstract] [Full Text] [Related]
2. The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry.
Mulder FVM; Peeters EFHI; Westerink J; Zwartkruis FJT; de Ranitz-Greven WL
Orphanet J Rare Dis; 2022 Jul; 17(1):252. PubMed ID: 35804402
[TBL] [Abstract][Full Text] [Related]
3. Tuberous Sclerosis Complex (TSC) Inactivation Increases Neuronal Network Activity by Enhancing Ca
Hisatsune C; Shimada T; Miyamoto A; Lee A; Yamagata K
J Neurosci; 2021 Sep; 41(39):8134-8149. PubMed ID: 34417327
[TBL] [Abstract][Full Text] [Related]
4. Lysosomal regulation of cholesterol homeostasis in tuberous sclerosis complex is mediated via NPC1 and LDL-R.
Filippakis H; Alesi N; Ogorek B; Nijmeh J; Khabibullin D; Gutierrez C; Valvezan AJ; Cunningham J; Priolo C; Henske EP
Oncotarget; 2017 Jun; 8(24):38099-38112. PubMed ID: 28498820
[TBL] [Abstract][Full Text] [Related]
5. Perfect match: mTOR inhibitors and tuberous sclerosis complex.
Luo C; Ye WR; Shi W; Yin P; Chen C; He YB; Chen MF; Zu XB; Cai Y
Orphanet J Rare Dis; 2022 Mar; 17(1):106. PubMed ID: 35246210
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress.
Zimmer TS; Korotkov A; Zwakenberg S; Jansen FE; Zwartkruis FJT; Rensing NR; Wong M; Mühlebner A; van Vliet EA; Aronica E; Mills JD
Brain Pathol; 2021 Sep; 31(5):e12949. PubMed ID: 33786950
[TBL] [Abstract][Full Text] [Related]
7. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
Mizuguchi M; Ohsawa M; Kashii H; Sato A
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
[TBL] [Abstract][Full Text] [Related]
8. Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop.
Henske EP; Rasooly R; Siroky B; Bissler J
Am J Physiol Renal Physiol; 2014 Feb; 306(3):F279-83. PubMed ID: 24226526
[TBL] [Abstract][Full Text] [Related]
9. Clinical, cellular, and molecular characterisation of cardiac rhabdomyoma in tuberous sclerosis.
Al Kindi HN; Ibrahim AM; Roshdy M; Abdelghany BS; Yehia D; Masoud AN; Simry W; Aguib Y; Yacoub MH
Cardiol Young; 2021 Aug; 31(8):1297-1305. PubMed ID: 33602381
[TBL] [Abstract][Full Text] [Related]
10. Mammalian target of rapamycin inhibitors for the treatment of astrocytic hamartoma in tuberous sclerosis complex (TSC).
Vorobichik Berar O; Tzadok M; Zloto O; Moroz I; Hecht I; Musika AA; Shlomovitz O; Fabian ID; Vishnevskia Dai V
Graefes Arch Clin Exp Ophthalmol; 2022 Sep; 260(9):3061-3068. PubMed ID: 35230473
[TBL] [Abstract][Full Text] [Related]
11. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
Boggarapu S; Roberds SL; Nakagawa J; Beresford E
Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
[TBL] [Abstract][Full Text] [Related]
12. Lymphedema in tuberous sclerosis complex.
Geffrey AL; Shinnick JE; Staley BA; Boronat S; Thiele EA
Am J Med Genet A; 2014 Jun; 164A(6):1438-42. PubMed ID: 24668795
[TBL] [Abstract][Full Text] [Related]
13. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
[TBL] [Abstract][Full Text] [Related]
15. Primary intestinal lymphangiectasia treated with rapamycin in a child with tuberous sclerosis complex (TSC).
Pollack SF; Geffrey AL; Thiele EA; Shah U
Am J Med Genet A; 2015 Sep; 167A(9):2209-12. PubMed ID: 25943403
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
Franz DN; Capal JK
Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
[TBL] [Abstract][Full Text] [Related]
17. [Tuberous sclerosis complex: A review].
Pfirmann P; Combe C; Rigothier C
Rev Med Interne; 2021 Oct; 42(10):714-721. PubMed ID: 33836894
[TBL] [Abstract][Full Text] [Related]
18. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus.
Doğan V; Yeşil Ş; Kayalı Ş; Beken S; Özgür S; Ertuğrul İ; Bozkurt C; Örün UA; Karademir S
J Trop Pediatr; 2015 Feb; 61(1):74-7. PubMed ID: 25344617
[TBL] [Abstract][Full Text] [Related]
19. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature.
Jóźwiak S; Sadowski K; Kotulska K; Schwartz RA
Pediatr Neurol; 2016 Aug; 61():21-7. PubMed ID: 27222056
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
